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A B S T R A C T
The monoamine hypothesis has been the prevailing hypothesis of depression over the last several
decades. It states that depression is associated with reduced monoamine function. Hence efforts to
increase monoamine transmission by inhibiting serotonin (5-HT) and norepinephrine (NE) transporters
has been a central theme in depression research since the 1960s. The selective 5-HT reuptake inhibitors
(SSRIs) and 5-HT and NE reuptake inhibitors (SNRIs) that have emerged from this line of research are
currently ﬁrst line treatment options for major depressive disorder (MDD). One of the recent trends in
antidepressant research has been to reﬁne monoaminergic mechanisms by targeting monoaminergic
receptors and additional transporters (e.g. with multimodal drugs and triple re-uptake inhibitors) or by
adding atypical antipsychotics to SSRI or SNRI treatment. In addition, several other hypotheses of
depression have been brought forward in pre-clinical and clinical research based on biological hallmarks
of the disease and efﬁcacy of pharmacological interventions. A central strategy has been to target
glutamate receptors (for example, with intravenous infusions of the N-methyl-D-aspartate (NMDA)
receptor antagonist ketamine). Other strategies have been based on modulation of cholinergic and g-
aminobutyric acid (GABA)ergic transmission, neuronal plasticity, stress/hypothalamic pituitary
adrenal(HPA)-axis, the reward system and neuroinﬂammation. Here we review the pharmacological
proﬁles of compounds that derived from these strategies and have been recently tested in clinical trials
with published results. In addition, we discuss putative treatments for depression that are being
investigated at the preclinical level and outline future directions for antidepressant research.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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The selective serotonin (5-HT) reuptake inhibitor (SSRI) and 5-
HT and norepinephrine (NE) reuptake inhibitor (SNRI) antide-
pressants that were launched during the 1980s and 1990s are
among the most successful drug treatments for psychiatric
disorders and still remain the ﬁrst line treatments for major
depressive disorder (MDD). Monoamine oxidase (MAO) inhibitors
have also been used for the treatment of MDD, but to a lesser
extent. SSRIs and SNRIs are often presented as two major classes of
antidepressants, with each class comprised of individual drugs that
are highly similar. However, thorough pharmacological character-
ization has shown that drugs from these two classes have different
levels of selectivity for their primary pharmacological target(s), i.e.* Corresponding author. Tel.: +1 201 350 0574; fax: +1 201 261 0623.
E-mail address: EDAL@lundbeck.com (E. Dale).
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0006-2952/ 2015 The Authors. Published by Elsevier Inc. This is an open access articNE and/or 5-HT transporters (NET and SERT, respectively).
Furthermore, they have notable afﬁnity for secondary receptor
or transporter targets at clinically relevant doses. For example,
among the SSRIs paroxetine shows afﬁnity for the NET and the
muscarinic cholinergic receptor, sertraline for the dopamine (DA)
transporter (DAT), ﬂuoxetine for the 5-HT2C receptor, citalopram
for the sigma1 and histamine (HA) H1 receptors, and escitalopram
for the sigma1 receptor [1–3]. Similarly, SNRIs show differences in
potency for SERT vs. NET with venlafaxine having a preference for
SERT over NET, and duloxetine being a more balanced drug with
respect to 5-HT and NE reuptake inhibitory potencies [4]. These
distinct pharmacological properties may lead to different clinical
efﬁcacy and/or tolerability proﬁles [4,5]. However, possibly due to
a lack of validated biomarkers that can reliably predict a patient’s
response to a given antidepressant, it appears that only 50% of
patients diagnosed with MDD go into clinical remission using
treatments from these two drug classes regardless of the drug
chosen [6]. For four consecutive treatment steps, the overallle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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group of patients who respond inadequately or not at all to
extensive therapeutic intervention. Moreover, the therapeutic
response to SSRIs/SNRIs is often delayed, requiring several weeks
of treatment. Many of the current antidepressants also have drug-
related adverse effects, such as nausea and sexual dysfunction
[7]. Thus, there is a large unmet need for additional treatment
options.
While the etiology and pathology underlying MDD still by large
remain unknown, many hypotheses of depression have been
brought forward in antidepressant research. Several of these
investigations have led to drug discovery efforts and in some cases
advanced into drug development programs (Fig. 1, Tables 1 and 2).
Interestingly, the rationale of these hypotheses often originated
from pharmacological manipulations performed in depressed
patients and was not based on an understanding of the
pathophysiology of disease.
Over the last 40–50 years the prevailing hypothesis of
depression has been the monoamine hypothesis which included
the catecholamine [8] and 5-HT [9] hypotheses. It originated from
mechanistic studies of the serendipitously discovered tricyclic
antidepressants (TCA) and MAO inhibitors. SSRIs and SNRIs that
came out of this line of research were conceived to mainly improve
tolerability of TCAs. Since the discovery of SSRIs and SNRIs, one
strategy in antidepressant research has been to reﬁne and expand
on the monoaminergic mechanisms by either targeting monoam-
inergic receptors or additional transporters in one molecule or by
augmenting the effects of SSRIs or SNRIs by adjunctive treatment
with another drug. The main objectives have been to improve
efﬁcacy and/or reduce the time to onset the therapeutic effect of
SSRIs and SNRIs. We review drug target proﬁles that came out of
these efforts and have been tested in the clinic in Section 2 and
Table 2. Additional target proﬁles that have only been investigated
in preclinical models are summarized in Table 1 and Section 5.
Other research efforts have focused on hypotheses of
depression that go beyond the monoamines (Fig. 1, Table 1).Fig. 1. Summary of current hypotheses of depression. Proposed hypotheses of depressio
targets see Table 1. Several biological processes involved in the etiology of depression 
different colors depicting heterogeneity in the etiology, diagnosis, and clinical manife
depression, the biological processes that they are proposed to impact and the human During the last decade there has been an increasing interest in
targeting glutamate neurotransmission. The interest in gluta-
mate targets precipitated from the spectacular clinical ﬁnding
that intravenous infusion of the N-methyl-D-aspartate (NMDA)
receptor antagonist ketamine can produce an immediate
antidepressant effect in patients with treatment-resistant
depression (TRD) [10]. Several other glutamate targets have
been deﬁned, some of which have been tested in the clinic and
are discussed in Section 3.
The neuroplasticity hypothesis of depression links to the
glutamate hypothesis. It is based on the observation that enhanced
neuronal plasticity (e.g. neurogenesis, dendritic branching, synap-
togenesis) appears to be a shared mechanism for antidepressants
and that depression risk factors, such as stress, reduce neuroplas-
ticity in the hippocampus and prefrontal cortex (PFC) (Fig. 1, [11]).
There have been extensive preclinical efforts to identify neuronal
plasticity related drug targets (Table 1 and Section 5), but the
hypothesis has so far not been validated clinically.
Additional hypotheses of depression have been based on
modulation of cholinergic transmission, stress/hypothalamic
pituitary adrenal (HPA)-axis, reward system, neuroinﬂammation
and g-butyric acid (GABA) transmission (Fig. 1, Table 1). Com-
pounds that were generated to test these theories (e.g. cortioco-
tropin releasing factor (CRF) antagonists, neurokinin (NK)
antagonists, kappa-opioid antagonists, Tumor Necrosis Factor
(TNF) a antibody) are discussed in Section 4. Compounds with
only preclinical mechanistic data are outlined in Table 1 and some
of them are discussed in Section 5. Finally, possible future
directions for antidepressant research are discussed at the end
of this review in Section 6.
2. Reﬁning and expanding monoaminergic mechanisms
beyond SSRIs and SNRIs
Whereas a general increase in extracellular monoamine levels
via inhibition of monoamine transporters may trigger a dampeningn and their associated drug targets are shown in the top oval. For a full list of drug
are listed in the middle oval. The bottom oval represents human depression with
station of the disease. Examples of relationships between different hypotheses of
disease are shown with dotted lines.
Table 1
Overview of hypotheses of depression and the associated drug target proﬁles. For the preclinical column, only target proﬁles with available tools compounds are listed. The
table does not include established antidepressants, such as TCAs, MAO inhibitors, SSRIs and SNRIs that have been on the market for many years.
Hypothesis Biological evidence in humans Drug target proﬁle
Clinical validation Preclinical validation only
Monoamine
The pathophysiology of depression involves
low levels of 5-HT, NE, and/or DA levels in
the CNS [9,207]
Antidepressant drugs elevate CNS levels of one
or more monoamines
Triple uptake inh 5-HT1A ago
(postsynaptic selective)
Tryptophan depletion can provoke relapse of
depression
Atypical antipsychotics
(add on)
5-HT2B ant
SSRIs, SNRIs, TCAs, MAOIs have clinical efﬁcacy Multimodal 5-HT2C ant
No direct evidence for a causal relation between
depression and monoaminergic dysregulation
5-HT3 ant
5-HT7 ant
a2A adrenoceptor ago
DA D2 ago
DA D3 ago
VMAT2 inh
TAAR1 ago
Glutamate
Depression involves dysfunctional
glutamate signaling in the brain which
leads to impaired neuroplasticity
[11,120]
Clinical efﬁcacy of ketamine NMDA open channel
blockers
AMPAkines
Changes in plasma and CSF levels of glutamate
and brain glutamate and glutamine levels in
MDD patients, but results are inconsistent
GluN2B ant
Reduced expression of excitatory amino acid
transporters in brain tissue from MDD patients
suggestive of impaired glutamate clearance
Glycine ago
mGluR2 NAM
mGluR5 NAM
Neuronal plasticity
Depression is ascribed to impaired
plasticity of neural circuits and
connections, and involves reduced
hippocampal neurogenesis, dendritic de-
branching and loss of dendritic spines and
synapses [187]
Most antidepressant treatments have shown to
increase neuronal plasticity in preclinical
studies
Neurogenesis stimulator
(NSI-189)
TrkB ago
Reduced hippocampal volume in MDD patients
Reduced neuronal and glial density in post
mortem brain tissue from MDD patients
Reduced serum levels of BDNF
No direct evidence for a causal relation to MDD
Cholinergic/adrenergic balance
Depression is associated with
hyperactivation of the cholinergic system
and as a consequence decreased activity
in the noradrenergic system
[163,164,167]
Cholinesterase inhibition exacerbates
depression
Muscarinic ant Muscarinic M3 ant
Muscarinic antagonists (TCAs, scopolamine)
have antidepressant activity
a4b2 nicotinic ant a7 nicotinic ago
No direct evidence for a casual relation to MDD
Anhedonia/Opioid
Anhedonia, a core symptom of depression,
is ascribed to a disrupted reward circuitry
where the brain opioid system plays a key
regulatory role. Stress induces the release
of dynorphin, which activates kappa
opioid receptors and down regulates DA
levels [169]
Kappa opioid agonist induces depression Kappa opioid ant
Nociceptin ant
Stress/HPA-axis
Depression is precipitated through a
dysregulation of the hypothalamic
pituitary-axis [146,148,208]
Stress can precipitate depressive episodes in a
subset of patients
CRF ant CB1 ago
Some depressed patients have hyperactive
adrenal glands, exhibit elevated responses to
stress and have elevated levels of CRF in
cerebrospinal ﬂuid
GR ant FAAH inh
NK1 ant
NK2 ant
Vasopressin ant
Orexin ant
Neuroinﬂammation
Pro-inﬂammatory and kynurenine
pathways are activated in depression and
contribute to the pathophysiology of
disease [209]
Immunosuppressant drugs can induce
depression
TNFa antibody KMO ant
High incidence of depression in patients with
inﬂammatory disorders
COX-2 inh P2x7 ant
Elevated levels of inﬂammatory markers in
plasma and post mortem brains from MDD
patients
GABA
Depression is associated with reduced
GABA neurotransmission in cortical
circuits [210]
Reduced CNS level of GABA in some MDD
patients
GABAA modulators
(neurosteroids)
GABAB ant
Abbreviations: Ant: antagonist; Inh: inhibitor; Ago: agonist; NAM: negative allosteric modulator.
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Table 2
Overview of recently approved antidepressants and drugs in clinical development for the treatment of MDD. *For approved drugs, doses are shown according to their drug
label; for experimental drugs, doses were taken from clinical trials according to https://clinicaltrials.gov.
Drug
(dose, mg/day, po)*
Putative MoA in MDD Treatment
regiment
Status Chemical structure
Vortioxetine (Lu AA21004)
(5–20)
5-HT3, 5-HT7 and 5-HT1D
ant, 5-HT1B partial ago, 5-HT1A
ago, SERT inh
Monotherapy Launched in 2014
S
N
NH
Vilazodone
(40)
5-HT1A partial ago, SERT inh Monotherapy Launched in 2011
N
H
N
N
N
O
H2N
O
Agomelatine
(25–50)
MT1 and MT2 ago, 5-HT2C ant Monotherapy Launched in 2009 O
N
H
O
Aripiprazole
(2–15)
D2 and 5-HT1A
partial ago, 5-HT2 ant
Add-on Launched in 2007
N
N
H
O O
N
Cl
Cl
Quetiapine
(150–300)
D2 and 5-HT2 ant Add-on Launched in 2009 S
N
N
N
O
HO
Symbyax1 (olanzapine and ﬂuoxetine)
(6–12 olanzapine, 25–50 ﬂuoxetine)
D2 and 5-HT2 ant Fixed dose
combination
of olanzapine
and ﬂuoxetine
Launched in 2009 H
N
N
S
H3C
N
N
H3C olanzapine
Brexpiprazole (OPC-34712)
(1–3)
D2 and 5-HT1A partial
ago, 5-HT2, alpha1B
and alpha2C ant
Add-on NDA submitted
in 2014
SN
N
H
O O
N
Cariprazine (RGH-188)
(2–4.5)
D2, D3 and 5-HT1A partial ago Add-on Phase 3
N
N
Cl
Cl
N
H
N
O
PNB-01
(pipamperone 15, citalopram 20–40)
D2, D4 and 5-HT2 ant Combination
of pipamperone
and citalopram
Phase 3 ongoing
but not recruiting
NH2O
N
F
O
N
pipamperone
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Table 2 (Continued )
Drug
(dose, mg/day, po)*
Putative MoA in MDD Treatment
regiment
Status Chemical structure
Amitifadine (DOV-21947/EB-1010)
(50–100)
DAT, SERT, NET inh Monotherapy Phase 3
N
H
Cl
ClH
Esketamine ((S)-enatiomer
of ketamine)
(0.20–0.40 mg/kg, i.v.;
14–84 mg intra nasal)
Non-competitive open-channel
blocker of NMDA receptors
Monotherapy Phase 2
NH
O Cl
CERC-301 (MK-0657)
(4–12)
NMDA GluN2B ant Add-on or
monotherapy
Phase 2
O N
O
H
N
N
N
F
GLYX-13 (rapastinel)
(5, 10 mg/kg, i.v.)
NMDA glycine site partial ago Monotherapy Phase 2
N
H O
OH
H
N
N
H2N
O
OH
H
O
O
NH2
H
H
NRX-1074
(1,5, 10 mg, i.v.)
NMDA glycine site partial ago Monotherapy Phase 2 Structure not published
Basimglurant (RG-7090)
(0.5, 1.5) [145]
mGluR5 NAM Monotherapy Phase 2
F
N
N
N
Cl
LY-2940094
(40)
Nociceptin ant Monotherapy Phase 2 Structure not published
ALKS-5461
(1:1 ratio for best efﬁcacy;
establishment of clinical dose
response is ongoing) [171]
Kappa ant Combination
of buprenorphine
and samidorphan
Phase 3
buprenorphine
samidorphan
* Abbreviations: Ant: antagonist; Ago: agonist; Inh: inhibitor; NAM: negative allosteric modulator.
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opposing activities (e.g. see regulation of 5-HT transmission via
pre- vs. postsynaptic stimulation of 5-HT1A receptors as discussed
below), targeting a single receptor may be inadequate due to
system redundancies (e.g. see selective peptide receptor targets
discussed in Section 4). Hence, multitarget (2 targets) or
multimodal (2 targets from different target classes [12])
approaches that involve additive or synergistic effects of selected
biological targets may be an attractive strategy for reﬁning and
improving efﬁcacy and/or tolerability of currently used anti-
depressants. These ideas have been extensively discussed in the
literature by several research groups [13–16] and are an
overarching theme for this section. The authors wish to highlight
in particular the very comprehensive reviews by Millan on this
topic [16–19].2.1. Add-ons to SSRIs and SNRIs in MDD
2.1.1. Augmentation mechanisms
For patients with an inadequate response to SSRI/SNRI therapy,
a common strategy has been to prescribe a second drug as an
adjunctive treatment in an attempt to either increase the efﬁcacy
of the ﬁrst antidepressant or to treat residual symptoms. This
strategy has been followed empirically by clinicians for many years
based on a patient’s symptoms. One of the ﬁrst hypothesis-driven
efforts that came out of preclinical research was to add a 5-HT1A
receptor partial agonist (or antagonist) to an SSRI [20]. This was
based on data showing that desensitization of 5-HT1A autorecep-
tors located in the raphe nuclei, a center for 5-HT producing cells,
was necessary for the maximum effect of SSRIs [20]. The
interpretation was that simultaneous application of a 5-HT1A
E. Dale et al. / Biochemical Pharmacology 95 (2015) 81–9786receptor antagonist with an SSRI would instantaneously inhibit the
negative feedback mechanism and allow for an immediate and
sufﬁcient increase in 5-HT levels to produce a fast antidepressant
response. However, since enhanced serotonergic neurotransmis-
sion through stimulation of postsynaptic 5-HT1A receptors was
hypothesized to be essential for the antidepressant effect of SSRIs,
it was important to only block presynaptic 5-HT1A receptors
[21]. Encouraging results from clinical studies using combinations
of SSRIs and pindolol, a 5-HT1A receptor partial agonist and a b-
adrenoceptor antagonist, showed a faster onset of antidepressant
effect than SSRIs alone and further fueled the interest in this
research area (e.g. [20]). Although pindolol was not developed as
an adjunctive treatment to SSRIs, the principle led to the initiation
of major efforts by pharmaceutical companies in the 1990s to ﬁnd
compounds that interacted with both 5-HT1A receptors and SERT.
Two novel multimodal antidepressants, vilazodone and vortiox-
etine, that are currently on the market for treatment of MDD, target
both 5-HT1A receptors and the SERT in their mechanism of action
(Section 2.3, Table 2).
Several additional 5-HT receptors (5-HT1B/1D, 5-HT2, 5-HT3, 5-HT4,
5-HT6 and 5-HT7 receptors) have also been investigated pre-clinically
and were shown to increase 5-HT neurotransmission beyond the
level achieved with SSRIs by impacting negative neuronal feedback
loops [22]. For instance, antagonism at postsynaptic 5-HT2A/2C
receptors was shown to increase 5-HT levels produced by SSRIs, most
likely via inhibition of GABAergic interneurons in the dorsal raphe
nucleus (DRN) [23]. Interestingly, the 5-HT2 receptor antagonism is a
prominent mode of action of atypical antipsychotics that are now
prescribed as add-ons to SSRIs and SNRIs.
2.1.2. Atypical antipsychotics as an augmenting strategy
Several atypical antipsychotics (olanzapine, risperidone, que-
tiapine, aripiprazole, paliperidone, ziprazidone and amisulpride)
have been tested in clinical MDD trials as a strategy to augment
SSRIs/SNRIs and some have obtained label claim for the treatment
of MDD [24]. Aripiprazole was the ﬁrst of the atypical anti-
psychotics to be approved in 2007 as an adjunct treatment in MDD
[25]. In 2009, quetiapine was also approved for augmentation in
MDD [26], and a ﬁxed dose combination of ﬂuoxetine and
olanzapine was approved for TRD the same year [27].
As described in Section 2.1.1, the synergistic effect between
atypical antipsychotics and SSRIs/SNRIs most likely involves the
inhibition of 5-HT reuptake and antagonism of 5-HT2A/C receptors
(Table 2), which leads to an increase in 5-HT levels beyond what is
achieved with an SSRI. Interestingly, there is very limited clinical
evidence for the use of selective 5-HT2 receptor antagonists as
standalone therapy [28]. Preclinical studies suggest that these
compounds might only be useful in augmentation strategies, likely
because an increased endogenous 5-HT tone, achieved through the
blockade of SERT, is required for a 5-HT2 receptor antagonist to
exert its functional activities [29].
Several other compounds are currently being investigated as
adjunctive treatments for MDD. A new drug application (NDA) was
recently ﬁled for the use of brexpiprazole (OPC-34712 [30], a
serotonin-dopamine activity modulator that is a partial agonist at
5-HT1A and D2 receptors and an antagonist at 5-HT2A and alpha1B/
2C adrenergic receptors [31] (Table 2). Furthermore, cariprazine, a
DA D2, DA D3 and 5-HT1A receptor partial agonist [32], is currently
undergoing clinical testing as adjunctive treatment for MDD
[33]. On the other hand, PNB-01, a combination of citalopram and a
low dose of pipamperone (D2, D4 and 5-HT2A receptor antagonist),
has failed to show any advantages over the treatment with
citalopram alone in one clinical study [34]. A follow-up phase
3 study has been registered at http://clinicaltrials.gov, but patients
have not yet been recruited (https://clinicaltrials.gov/show/
NCT01312922).In conclusion, the add-on of antipsychotics to SSRIs/SNRIs has
shown improved clinical efﬁcacy over the ﬁrst line treatment.
However, the strategy has obvious limitations due to the potential
risk of drug–drug interactions, which may complicate achieving the
right therapeutic levels, as well as the stigmatization associated with
the use of antipsychotics in the treatment of MDD [12].
2.1.3. Additional augmentation strategies
Several other augmentation strategies have been pursued, but
with limited success. The selective NE reuptake inhibitor,
edivoxetine, and the dextroamphetamine prodrug, lisdexamfeta-
mine, showed no augmentation effect with SSRIs in the clinic, and
the programs were recently discontinued [35,36]. An add-on of the
5-HT1B/1D receptor antagonist elzasonan (CP-448187) to sertraline
was also discontinued in 2008 with no published data on its
clinical efﬁcacy (http://clinicaltrials.gov/show/NCT00275197).
2.2. Triple reuptake inhibitors
As a consequence of the SNRI success in treatment of MDD,
researchers have pursued the idea of developing compounds
blocking all three monoamine transporters, the so-called 5-HT, NE,
DA reuptake inhibitors (SNDRIs), or triple reuptake inhibitors. This
concept was based on the positive role of DA on the reward system
and the fact that anhedonia is a prominent symptom in a subset of
MDD patients, especially those with melancholic depression
[37]. This hypothesis was further supported by positive clinical
augmentation studies with DA-enhancing drugs [37].
During the past decade, several SNDRI drug candidates have
been developed and tested in the clinic. The main concerns with
these drugs have been how to avoid exaggerated dopaminergic
stimulation and abuse liability. Amitifadine (DOV-21947 or EB-
1010), which was among the ﬁrst SNDRI drug candidates,
preferentially enhanced 5-HT with 1:2:8 potency rankings for
the inhibition of SERT, NET, and DAT, respectively [38]. Amitifadine
showed efﬁcacy in a small clinical proof-of-concept (PoC) study.
However, amitifadine did not meet the clinical endpoint in a
subsequent larger double-blind placebo-controlled study in MDD
patients who had failed one treatment with a ﬁrst-line antide-
pressant [39]. Additional clinical studies in MDD are being planned
with this compound at higher doses.
Other efforts to develop more balanced SNDRIs with similar Ki
values for SERT, NET and DAT have also failed, in most cases before
reaching PoC studies. Two compounds, NS-2359 (GSK-372475)
and liafensine (BMS-820836), were evaluated in phase 2 clinical
studies, but both programs were terminated. In a large phase
2 program with 900 patients, NS-2359 was found neither
efﬁcacious nor well tolerated, whereas comparators paroxetine
and venlafaxine separated signiﬁcantly from placebo [40].
Thus, in spite of signiﬁcant investments, the clinical value of
SNDRIs for the treatment of depression remains to be demonstrat-
ed. There are still several SNDRIs in preclinical development (e.g.
LPM570065, [41]) that might be clinically tested at a later time.
However, the failure of the DA-releasing compound lisdexamfe-
tamine to show efﬁcacy as adjunctive treatment in MDD patients
who responded inadequately to monotherapy with an SSRI or SNRI
[36] is not supportive of a role of enhanced DA transmission in
promoting antidepressant activity. SNDRIs might have better
efﬁcacy in a well-deﬁned subset of MDD patients with prominent
symptoms of anhedonia (i.e. in melancholic depression). This
remains to be substantiated in future clinical studies.
2.3. Multimodal antidepressants
Another strategy to augment 5-HT transmission beyond what is
achieved with an SSRI has been to target 5-HT receptors in
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cology behind these efforts is described in Section 2.1. This strategy
has led to a new class of antidepressants with a multimodal
mechanism of action [12]. Vilazodone, a 5-HT1A receptor partial
agonist and SERT inhibitor (Section 2.3.1) and vortioxetine, a 5-
HT1A receptor agonist, 5-HT1B receptor partial agonist and 5-HT3,
5-HT7 and 5-HT1D receptor antagonist and SERT inhibitor (Section
2.3.2), are two multimodal antidepressants that have recently
received market authorization for the treatment of MDD. In
addition, a positive dose-ﬁnding clinical study has been performed
in MDD patients with tedatioxetine (Lu AA24530), a 5-HT3 and 5-
HT2C receptor antagonist and SERT inhibitor, results from which
were published in a press release form [42].
2.3.1. Vilazodone
Vilazodone (EMD 68843) has been approved in the United
States (US) for the treatment of MDD in adults. The drug originates
from a drug discovery program undertaken in the mid 1990s and
was taken through a phase 2 clinical development program in MDD
patients in the late 1990s until the early 2000s [43]. The program
was discontinued due to disappointing results [44]. However, later
the clinical development program was reinitiated and developed in
the US only. After completion of two positive placebo-controlled
phase 3 studies the FDA granted a market authorization in 2011.
In spite of a long development time, the preclinical and the
clinical literature on vilazodone are limited. In preclinical studies,
vilazodone acts as a partial agonist at 5-HT1A receptors and a SERT
inhibitor. It increases extracellular 5-HT beyond levels seen with
SSRIs in microdialysis studies in rats without affecting cortical NE
and DA levels [45]. The potentiating effect on 5-HT levels has been
ascribed to vilazodone’s partial agonism at 5-HT1A receptors
[46]. The direct effect at 5-HT1A receptors was also shown in
electrophysiology recordings in which vilazodone acutely sup-
pressed the ﬁring rate of serotonergic DRN neurons in 5-HT
depleted rats where SSRIs do not work [47]. Interestingly and
unexpectedly (given the rationale for its pharmacological proﬁle
[Section 2.1.1]), the time course for desensitization of 5-HT1A
autoreceptors was similar to that of an SSRI and still required
14 days administration of vilazodone [47].
The lack of effect of vilazodone on NE and DA levels in the cortex
is puzzling since selective 5-HT1A receptor agonists (both full and
partial agonists) are known to increase cortical levels of NE and DA
[48,49]. However, increased 5-HT release has been shown to
attenuate cortical release of NE and DA [50–52]. It is therefore
possible that these two opposing effects result in a neutral effect of
vilazodone on NE and DA. Whereas SSRIs have been associated
with 5-HT-mediated cognitive and emotional blunting and weaker
effects on anhedonia than drugs that also enhance NE and DA
release [53–57], there are no data for vilazodone on these
measures. Furthermore, there is no information on vilazodone’s
effect on NE and DA release after repeated dosing.
Vilazodone is active in classical behavioral models predictive of
antidepressant and anxiolytic activity, but in some instances the
dose-response curve was biphasic, possibly due to its partial
agonistic activity at 5-HT1A receptors (a partial agonist will act as
an antagonist in a system with an elevated 5-HT tone) and the
involvement of both pre- and post-synaptic 5-HT1A receptors in
mediating these effects [58]. Since a clinical dose response relation
has not been established (see below), it is unknown whether this
biphasic dose response relation translates into the clinic.
Five double-blind randomized placebo-controlled phase 2 stud-
ies and two phase 3 studies in adult MDD patients were the basis
for efﬁcacy evaluation of the NDA [59]. Vilazodone did not separate
from placebo on the primary endpoint in any of the phase 2 studies.
In three of the phase 2 studies that included an active reference, the
reference also failed to separate from placebo, suggesting thatthese were failed studies [59]. Two short-term phase 3 studies
compared vilazodone at 40 mg/day to placebo, and both studies
met the primary endpoint [59]. The most common adverse effects
were related to the gastrointestinal tract and sleep quality, which
are well-known adverse effects of SERT inhibitors and selective 5-
HT1A receptor agonists [60]. Hence, vilazodone which displays
both activities has relatively high rates of gastrointestinal adverse
effects such as diarrhea, nausea and vomiting and requires dose
titration over two weeks in order to reach the daily target dose of
40 mg [59,61].
According to https://clinicaltrials.gov, several clinical studies
with vilazodone are still ongoing, some of which are phase
4 commitments related to the FDA approval (e.g., long-term
efﬁcacy and safety, efﬁcacy in adolescents and in a geriatric
population in MDD), others are directed toward investigating the
efﬁcacy of vilazodone in other indications, including generalized
anxiety disorder, social anxiety disorder and post-traumatic stress
disorder. In conclusion, vilazodone is a new multimodal antide-
pressant with interesting pharmacology, but it is too soon to
evaluate its impact in everyday clinical practice.
2.3.2. Vortioxetine
The drug discovery program that led to the development of
vortioxetine (Lu AA21004) also had its origins in the 5-HT
augmentation hypothesis (Section 2.1.1). However, during the
drug discovery phase of the project the target proﬁle was
redirected toward a combination of SERT inhibition, 5-HT1A
receptor agonism and 5-HT3 receptor antagonism [62], in part
because it was found that the 5-HT3 receptor antagonism
potentiated the increase in extracellular 5-HT levels produced
by SERT inhibition [63]. Vortioxetine has been approved in major
markets since 2013, including the US, European Union (EU),
Canada, South Africa, Australia, Mexico and South Korea, for the
treatment of MDD.
Vortioxetine is a 5-HT3, 5-HT7 and 5-HT1D receptor antagonist, a
5-HT1B receptor partial agonist, a 5-HT1A receptor agonist and a
SERT inhibitor in cellular assays and shows antidepressant and
pro-cognitive activities in preclinical animal models [62,64]. It
increases 5-HT (beyond that of an SSRI), NE, DA, acetylcholine
(ACh), and HA levels in rat brain regions associated with MDD, such
as the PFC and the ventral hippocampus [63,65]. Furthermore,
vortioxetine enhances glutamatergic neurotransmission, most
likely through inhibiting GABA interneurons [66,67]. The 5-HT3
receptor antagonism plays a prominent role in the pharmacology
of vortioxetine since the 5-HT3 receptor agonist SR57227 can
reverse the potentiating effect of vortioxetine on glutamatergic
and serotonergic transmission [68]. However, the modulation of
other 5-HT receptor subtypes, including antagonism of 5-HT7
receptors and partial agonism at 5-HT1B receptors, might also
contribute to vortioxetine’s overall pharmacological effects
[69,70].
Vortioxetine exhibits antidepressant- and anxiolytic-like prop-
erties in classical monoamine-sensitive behavioral models of
depression, but also in models that are insensitive to SSRIs/SNRIs,
such as the progesterone withdrawal model [71] and in aged mice
[72]. Interestingly, and different from any other antidepressants
tested including SSRIs, vortioxetine had no effect on sucrose
drinking in a chronic mild stress model of depression/anhedonia
[64]. The mechanism underlying this lack of effect is currently not
understood and it does not translate into reduced clinical efﬁcacy
on anhedonia related symptoms, as measured by clinical rating
scales [64]. To date there are no studies that speciﬁcally assess the
effect of vortioxetine on emotional blunting and given vortiox-
etine’s complex modulation of multiple neurotransmitter systems,
this question can only be addressed with empirical testing. Finally,
in line with its mechanistic data and different from SSRIs,
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including attention/vigilance measured by quantitative electroen-
cephalography [73], executive function, memory, and learning in
animal models (reviewed in [64]). Taken together, these preclinical
observations indicate that vortioxetine has a complex pharmaco-
logical proﬁle that differs from those of the SSRIs and SNRIs.
The implications of vortioxetine’s modulation of multiple
neurotransmitter systems on its antidepressant and pro-cognitive
potential are complex and the net effect can only be evaluated
through empirical data. For instance, the increased 5-HT, NE and DA
neurotransmission after acute and chronic dosing would, in line
with the monoamine hypothesis, favor vortioxetines’s antidepres-
sant potential. On the other hand, increased 5-HT level may dampen,
whereas the enhanced NE and DA levels may favor a pro-cognitive
proﬁle. Vortioxetine’s increased ACh transmission would, in line
with the cholinergic hypothesis of depression, disfavor its antide-
pressant activity. However, microdialysis studies indicate that the
magnitude of the effect produced by vortioxetine on this neuro-
transmitter system is much less pronounced than that obtained with
the cholinesterase inhibitor donepezil (G. Smagin, unpublished
observation), and there is no effect on ACh release after chronic
dosing with vortioxetine [63,65]. Thus, the cholinergic enhancing
properties of vortioxetine may therefore contribute to its pro-
cognitive activities, but may have less of an impact after repeated
dosing. In addition, vortioxetine produces a sustained increase in
cortical and hippocampal HA transmission after chronic dosing
[74]. The brain HA system plays an important role in promoting
cognitive function and attention. Thus, vortioxetine-induced
increase of HA levels is likely to contribute to its pro-cognitive
effects. The effect of HA signaling on mood is poorly deﬁned.
However, we cannot exclude the possibility that HA-dependent
enhancement in cognition can indirectly make positive contribu-
tions to mood. Finally, vortioxetine’s modulation of glutamate
neurotransmission should favor its antidepressant and pro-cogni-
tive properties since several measures indicate that vortioxetine
promotes glutamate dependent neuronal plasticity to a degree that
is superior to SSRIs. Vortioxetine, unlike the SSRI escitalopram,
disinhibits 5-HT-induced suppression of pyramidal neuron activity
in rat hippocampal slices and consequently increases long-term
potentiation, a measure of increased synaptic plasticity [66]. Fur-
thermore, gene expression studies show that vortioxetine, unlike
ﬂuoxetine, acutely activates genes associated with neuroplasticity in
rats (i.e. mammalian target of rapamycin (mTOR), metabotropic
glutamate 1 (mGlu1) receptor, spinophillin, protein kinase C (PKC)a,
Homer1, Homer3) [75]. Similarly, after chronic dosing, vortioxetine
activates neuronal plasticity related genes, improves visual spatial
memory deﬁcits, and shows antidepressant-like activity in
12 months old mice, whereas ﬂuoxetine has no effects on any of
these measures in old mice [76]. Vortioxetine also increases cell
proliferation in the hippocampal dentate gyrus faster than ﬂuoxe-
tine (3 days for vortioxetine compared to 10 days for ﬂuoxetine) [77]
in rats, and produces a larger degree of dendritic branching than
ﬂuoxetine after two weeks of dosing in mice [78].
Vortioxetine’s neuroplasticity enhancing properties support a
notion that its antidepressant and pro-cognitive proﬁles are
meditated, at least to some extent, through increased glutamate
neurotransmission and neuroplasticity. It is important to note that
although enhanced glutamate neurotransmission is thought to
favor plasticity and subsequent antidepressant and pro-cognitive
effects, it is also clear that exaggerated glutamate release (for
instance, in relation to stress) can be neurotoxic (reviewed in
[11,79]). Vortioxetine’s effects on glutamate appear to be limited to
enhanced neuronal function. This has been shown in microdialysis
studies where no change in extracellular glutamate was detected
in the ventral hippocampus and PFC upon the treatment with
vortioxetine [80].In a comprehensive clinical program for MDD, vortioxetine
showed dose-dependent efﬁcacy and was well tolerated (e.g.,
[81]). The short-term (6 or 8 weeks) program consisted of
12 randomized double-blind placebo-controlled studies and one
12-week study in MDD patients showing an inadequate response
to SSRIs or SNRIs vs. agomelatine [64]. On the pre-speciﬁed
primary efﬁcacy endpoint, vortioxetine was statistically signiﬁ-
cantly superior to placebo in seven of the placebo-controlled
studies, and the observed effect size was clinically relevant
[64]. Vortioxetine was also superior to agomelatine [64]. Long-
term efﬁcacy of vortioxetine was shown in a placebo-controlled
relapse-prevention study [82] and in two open-label extension
studies [83,84]. Finally, in line with preclinical support for
vortioxetine having pro-cognitive activities, vortioxetine showed
a positive effect on pre-deﬁned cognition outcome measures in
three double-blind randomized placebo-controlled studies of
cognitive dysfunction in MDD patients, two of which included
the active reference duloxetine [85–87].
Vortioxetine was well tolerated in short-term as well as long-
term clinical studies, with a low level of discontinuation
symptoms, likely due to its relatively long half-life. The adverse
effect with the highest incidence was nausea, which in general was
of mild or moderate intensity and transient. There was a relatively
low incidence of sexual dysfunction and sleep disruption
[88,89]. Overall, vortioxetine showed strong evidence for antide-
pressant efﬁcacy with good tolerability [90]. In addition, it showed
improvement of cognitive dysfunction in patients with MDD.
Vortioxetine’s clinically effective dose range of 5–20 mg/day
spans from approximately 50 to >80% SERT occupancy [91]. Given
that effective doses of SSRIs typically correspond to at least 80% SERT
occupancy [92], the results at <80% SERT occupancy support the
hypothesis that the antidepressant effects of vortioxetine arise from
both receptor modulation and inhibition of the SERT. However, it has
been difﬁcult to determine vortioxetine’s occupancy at 5-HT
receptors in humans. An attempt to determine 5-HT1A receptor
occupancy using the 5-HT1A receptor antagonist radiotracer
[11C]WAY100-635 in a positron emission tomography (PET) study
failed to demonstrate occupancy of vortioxetine at this receptor
[93]. However, using a 5-HT1A receptor antagonist radiotracer may
not be an appropriate method of estimating receptor occupancies for
a drug like vortioxetine that acts as a full agonist. The 5-HT1A
receptor complex can exist in a coupled or decoupled state with its G
protein signaling complex. The decoupled state is associated with
low agonist afﬁnity, whereas the antagonist afﬁnity is unaffected by
the coupling state [94–96]. Thus, vortioxetine might not displace 5-
HT1A antagonist binding at 5-HT1A receptors that are in decoupled
state. Furthermore, even though selective 5-HT1A receptor agonist
and 5-HT1B receptor antagonist radiotracers have become available
for human use over the last few years (i.e. [11C]CUMI-101 and
[11C]AZ10419369, respectively [97,98]), they might not be useful for
a drug like vortioxetine because these ligands are sensitive to
changes in extracellular 5-HT. Since 5-HT1A and 5-HT1B receptors
have a high afﬁnity for 5-HT, elevated 5-HT levels produced by SERT
inhibition would likely compete with vortioxetine’s displacement of
these radiotracers. There are no radiotracers for 5-HT3 and 5-HT7
receptors that have been validated for human use. Thus, vortiox-
etine’s occupancy at 5-HT receptors in humans remains to be
demonstrated.
In conclusion, even though vortioxetine’s primary drug targets
are serotonergic, the complexity of the 5-HT system and the fact
that vortioxtine only modulates a subset of 5-HT receptors lead to
its complex pharmacological proﬁle that overlaps with a number of
hypotheses of depression. Future clinical studies with a transla-
tional focus will hopefully provide further insights into how
vortioxetine’s preclinical proﬁle may deﬁne its efﬁcacy in
subpopulations of patients with MDD.
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Another approach to treat the symptoms of depression has been
to target 5-HT beyond reuptake. An example of this is agomelatine,
a melatonin MT1 and MT2 receptor agonist and a 5-HT2C receptor
antagonist [99]. 5-HT is catabolized into melatonin in the pineal
gland via a two-step enzymatic process [100]. Dysregulation in 5-
HT production and catabolism may affect melatonin levels and
thus be a cause of the sleep disturbances often observed in
depressed patients. Agomelatine bypasses melatonin production
by targeting MT1 and MT2 receptors and affects the 5-HT system
directly by antagonizing 5-HT2C receptors. The drug was developed
in the 1990s and has been approved in several regions, including
EU, South Africa, Australia and Canada for the treatment of MDD. A
phase 3 clinical program was also initiated in the US, but then
discontinued possibly due to a potential requirement of liver
function monitoring in patients taking the drug [101].
An extensive preclinical and clinical program has been
conducted on agomelatine and almost 500 research papers and
multiple reviews have been published. Preclinically, agomelatine
has been shown to resynchronize disrupted circadian rhythms in
rodents, by activating the MT1 and MT2 receptors in the
suprachiasmatic nucleus (SCN) and by inhibiting the 5-HT2C
receptors (reviewed in [99,102]). Agomelatine has demonstrated
antidepressant-like effects in various classical animal models of
depression, including the forced swim test [103], chronic mild
stress [104] and learned helplessness [105]. Again, in several of
these models the antidepressant effect depended on its combined
action at MT receptors and antagonism at 5-HT2C receptors
[103,105]. Acute treatment with agomelatine was shown to increase
extracellular levels of DA and NE without increasing 5-HT levels in
the PFC [106]. On the other hand, chronic treatment with
agomelatine increased neuronal ﬁring of both dopaminergic cells
in the ventral tegmental area and of serotonergic cells in the DRN and
thereby enhanced DA and 5-HT release[107], possibly via indirect
connections of the SCN with midbrain monoaminergic nuclei
[108]. Taken together, these results link agomelatine’s mechanism of
action to the modulation of monoaminergic transmission, but also
differentiate its proﬁle from those of SSRIs and SNRIs.
The above mentioned pharmacological properties of agomelatine
were evident in the clinic. In multiple clinical trials, including three
phase 2 double-blind placebo-controlled studies and several studies
with active references, agomelatine was efﬁcacious in reducing
depressive symptoms, improving sleep quality and re-setting
disrupted circadian rhythms [109]. Furthermore, it showed an
ability to address anhedonia [110] and emotional blunting
[111]. Agomelatine was well tolerated with no acute serotonergic
side effects [112], lack of discontinuation syndrome [113] and
minimal sexual dysfunction [114]. The main adverse effect was
elevated levels of serum transaminase in some of the subjects, which
might be indicative of liver damage [115]. In summary, agomelatine
represents a novel and different mechanism for treating MDD with
substantial positive preclinical and clinical data, but its approval and
use have been quite limited. Intriguingly, no other compounds with a
similar mechanism of action have been brought to the clinic.
However, since agomelatine’s proﬁle is different from those
observed with SSRIs and SNRIs [116], mechanisms underlying its
responses and interactions between the melatonin and 5-HT systems
perhaps should be explored further in antidepressant research.
3. Beyond monoamines – the glutamate track
3.1. Ketamine and other NMDA receptor modulators
Recent interest in the role of glutamatergic transmission in
depression came from the seminal clinical study of Berman et al.demonstrating that a single intravenous dose of the NMDA open
channel blocker ketamine can produce immediate and long-lasting
antidepressant effects in patients with TRD [10]. Follow-up studies
conﬁrmed this observation and now ketamine is used as a
treatment option for difﬁcult-to-treat MDD patients [117]. Despite
its efﬁcacy in difﬁcult-to-treat patients, clinical use of ketamine is
limited, mainly due to its psychotomimetic adverse effects and
abuse liability [118]. Thus, considerable efforts have been made to
elucidate ketamine’s mechanism of action and to develop drugs
with a similar clinical efﬁcacy, but with a more favorable safety
proﬁle. Several such compounds are currently being investigated
in the clinic and are discussed at the end of this section.
Ketamine is a non-competitive open-channel blocker of
glutamatergic NMDA receptors. It binds to NMDA receptors in
their open state, gets trapped inside the channel pore after the
receptor closes, and slowly dissociates after the receptor is
reactivated by its endogenous ligand [119]. A prominent hypothe-
sis is that ketamine preferentially targets NMDA receptors located
on GABAergic interneurons because these cells are more metabol-
ically active than pyramidal neurons and have a higher probability
of NMDA receptors being in an open state. Blockade of NMDA
receptors by ketamine would prevent interneurons from ﬁring
which in turn would disinhibit pyramidal cells producing a
targeted burst of glutamate in the brain [120]. In support of this
hypothesis, the microdialysis study by Moghaddam et al. demon-
strated that administration of ketamine causes a rapid and
transient increase in extracellular glutamate in the medial PFC
in rats [121]. The glutamate burst is thought to mediate the
antidepressant effects of ketamine, in part by activating intracel-
lular pathways relevant for neuronal plasticity and synaptogenesis
[120,122–124]. For instance, Li et al. showed that treatment with
ketamine enhances signaling through post-synaptic a-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors
and increases the number of dendritic spines in cortical layer V
pyramidal neurons in the PFC [123]. Ketamine also reverses deﬁcits
in the spine number and reduces anhedonia produced by exposure
to chronic unpredictable stress [124]. These effects are at least in
part mediated by activation of the mTOR signaling pathway and
release of brain-derived neurotrophic factor (BDNF), both of which
have been linked to the formation of new synapses [122,123]. How-
ever, ketamine has also been shown to activate the immediate
early activity gene Arc (activity regulated cytoskeleton associated
protein) [125], which is known to down-regulate expression of
AMPA receptors [126]. Thus, ketamine might not only be
increasing synaptic activity, but rather normalizing it and bringing
it to an optimal level.
In summary, preclinical research has started to provide insights
into the molecular mechanisms of action of ketamine. However,
ketamine has also been shown to produce antidepressant-like
behavioral responses in mice lacking NMDA receptors in parval-
bumin positive interneurons [127]. This study questions the
dependence of ketamine’s effect on the blockade of NMDA
receptors on GABAergic cells. Furthermore, ketamine does not
produce antidepressant effects in 5-HT deprived animals [128],
suggesting that 5-HT tone is required for ketamine’s antidepres-
sant activity. Additional targets of ketamine, such as sigma
receptors [129], monoamine transporters [130], and 5-HT1B
receptors [131], as well as pharmacological activities of ketamine’s
metabolites, might collectively contribute to its antidepressant
effect. Thus, additional research is needed to elucidate ketamine’s
mechanism of action.
Clinical data on the efﬁcacy of ketamine in depression came
mostly from small open-label studies and case reports, with only a
few crossover studies [10,132,133]. These studies reported a rapid
acting antidepressant effect of ketamine in difﬁcult-to-treat or TRD
patients. A single intravenous infusion of a low sub-anesthetic dose
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4 h and this response was sustained for several days or even weeks
[133–135]. In about 50–80% of patients, depressive symptoms and
even suicidal ideation weakened after a single infusion of
ketamine, but repeated administration of the drug was required
to maintain its effect [135]. Blier et al. have recently reported that
several monthly infusions with ketamine can lead to remission
without the development of addiction or other adverse effects
[136]. However, the consequences of long-term treatment with
ketamine are still largely unknown which limits its clinical use. The
(S)-enantiomer of ketamine, esketamine, is currently being tested
in phase 2 clinical trials in MDD after both intravenous and
intranasal administration, but no data on its efﬁcacy have been
reported yet according to https://clinicaltrials.gov.
As mentioned in the beginning of the section, ketamine’s
psychotomimetic adverse effects and abuse liability largely
prevent its use in the general population of MDD patients. Thus,
several strategies have been put forward to develop NMDA
receptor modulators with the rapid ketamine-like antidepressant
effect, but a better tolerability. One such strategy has been to
develop compounds with a faster dissociation rate, resulting in a
lower amount of trapping inside the NMDA channel [119]. An
example of this is lanicemine (AZD6765), initially developed for
the treatment of stroke. Lanicemine’s efﬁcacy in TRD was recently
assessed in two small clinical trials [137,138]. Since the trapping
rate of NMDA open channel blockers is thought to be correlated
with psychotomimetic and dissociative effects [119], it was
hypothesized that lanicemine would exhibit ketamine-like anti-
depressant efﬁcacy without psychotomimetic symptoms. As
predicted, lanicemine did not induce psychotomimetic or disso-
ciative effects in clinical trials [137,138]. However, a single
infusion of lanicemine failed to produce a sustained antidepressant
effect in TRD patients [138]. Interestingly, in the study by Sanacora
et al., repeated dosing with lanicemine (three times a week for
three weeks) had a sustained antidepressant response after one to
two weeks of treatment [137]. Thus, additional research with
multiple dosing regimens is needed to investigate the efﬁcacy of
lanicemine in TR MDD.
Memantine is another low-trapping NMDA receptor antagonist
that has been investigated for antidepressant activity. Memantine
is approved for the treatment of moderate-to-severe Alzheimer’s
disease. However, it did not show a signiﬁcant antidepressant
response in patients with MDD in one clinical study [139] where
memantine was administrated orally over several weeks. It would
be interesting to investigate whether an intravenous route of
administration of memantine, which achieves steady state drug
levels much faster than the oral route, would be efﬁcacious.
Another strategy to develop an improved ketamine-like agent
has been to target selective NMDA receptor subunits. NMDA
receptors are tetramers composed of two major subunits, GluN1
and GluN2. There are eight splice variants of GluN1 subunits and
four different GluN2 subunits (GluN2A, GluN2B, GluN2C and
GluN2D) [140]. Ketamine is a non-selective NMDA receptor
antagonist. Based on preclinical work, it was proposed that a
selective GluN2B antagonist would retain antidepressant activity
without having psychotomimetic effects [117,140]. Two GluN2B
antagonists have been tested in the clinic with published results.
Traxoprodil (CP-101,606) was tested in a small augmentation
study in patients who had responded inadequately to paroxetine. A
single intravenous infusion of traxoprodil showed a signiﬁcant
improvement in the paroxetine response ﬁve days after the
infusion, and the response lasted for one week [141]. Traxoprodil
was not tested as a stand-alone therapy. Some psychotomimetic
effects were still observed with traxoprodil, but they were reduced
when the dose was decreased. Another GluN2B antagonist CERC-
301 (MK-0657) failed to show antidepressant efﬁcacy on theprimary outcome measure, but showed signiﬁcant effects on the
secondary measures in one clinical trial [142]. It was a small study
of 21 TRD patients and only ﬁve patients completed the study. A
follow-up phase 2 study with CERC-301 as an adjunctive treatment
in TRD has been recently completed, but its results have not been
reported yet (https://clinicaltrials.gov/show/NCT01941043). It will
be interesting to know whether CERC-301 shows antidepressant
efﬁcacy in that large clinical trial.
A different way to modulate NMDA receptors is through their
glycine co-agonist site. An example of such an approach is GLYX-13
(rapastinel), a tetrapeptide that functions as a partial agonist at the
glycine site [143]. GLYX-13 is currently being developed as an
adjunctive therapy for MDD. The compound showed antidepres-
sant activity in a phase 2 clinical study, results from which have
been published in a review paper [143]. Administration of a single
intravenous dose of GLYX-13 in patients resistant to at least one
antidepressant agent resulted in improved depression scores
without producing psychotomimetic side effects [143]. As with
ketamine, the improvement was sustained, lasting for several days.
However, there was no dose response relationship and the highest
dose tested (30 mg/kg) did not differentiate from placebo. It will be
important to know whether these encouraging ﬁndings will be
replicated in larger clinical programs.
In conclusion, several NMDA receptor modulators have shown
antidepressant activity, but these results came from relatively
small clinical studies. While promising, these ﬁndings need to be
conﬁrmed in large, adequately powered clinical trials at doses
where the target engagement ideally is ensured. It still remains to
be determined whether the NMDA receptor antagonism is the only
target for ketamine and whether other NMDA receptor modulators
can be as efﬁcacious as ketamine in the treatment of MDD,
optimally without producing the psychomimetic adverse effects.
3.2. Metabotropic glutamate receptor modulators
Another approach that has been taken to modulate glutamate
neurotransmission is via the targeting of metabotropic glutamate
(mGlu) receptors. The mGlu5 receptors are functionally and
physically linked to NMDA receptors and may offer an alternative
and possibly a safer way of regulating NMDA receptor function.
mGlu5 receptors are also involved in regulation of AMPA receptor
internalization, a key mechanism for the regulation of synaptic
plasticity which is thought to be important in depression
[144]. Another type of mGlu receptors, the mGlu2/3 receptors,
are expressed presynaptically and involved in regulation of
glutamate release. Two mGlu receptor modulators have been
recently brought to the clinic: decoglurant (RG1578), an mGlu2
receptor negative allosteric modulator (NAM), and basimglurant
(RG7090), an mGlu5 receptor NAM, for the treatment of depression
and TRD, respectively. Results from the ﬁrst clinical study with
basimglurant as an adjunctive treatment to an SSRI have been
recently reported [145]. Although the primary outcome measure
was not met in this study, adjunctive treatment with basimglurant
showed antidepressant effect in several secondary measures and
needs to be explored further.
4. Other target proﬁles with clinical validation data
Several other mechanisms have been investigated in clinical
trials of MDD, but unfortunately with limited success. Extensive
literature suggesting a link between stress and depression has
prompted the so-called ‘‘stress hypothesis of depression’’, and
substantial efforts have been made to identify drugs that can
modulate the HPA-axis for the treatment of MDD [146,147]
(Table 1). One theory has been that stress-induced dysregulation of
the HPA-axis leads to depressive episodes via loss of synapses in
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[148]. Mifepristone, an antagonist of glucocorticoid receptors that
are activated during stress, has been investigated in a comprehen-
sive clinical program for psychotic depression for more than
10 years [149]. However, due to disappointing clinical results the
program was recently discontinued [150].
Based on clinical research showing that some MDD patients
have a hyperactive adrenal gland, exhibit elevated responses to
stress, and have increased levels of CRF in the cerebrospinal ﬂuid, it
was hypothesized that CRF1 receptor antagonists could be
efﬁcacious in the treatment of MDD [146]. Several CRF1 receptor
antagonists have been tested in the clinic. The ﬁrst small open-
label study with the CRF1 receptor antagonist NBI-30775/R121919
had positive results [151]. However, a later double-blind
randomized placebo-controlled phase 2 study with the CRF1
receptor antagonist CP-316,311 failed to demonstrate its efﬁcacy
in MDD [152]. As a result, several drug companies removed CRF1
receptor antagonists from their drug pipelines. Thus, despite of a
strong preclinical rationale and the availability of biomarkers to
ensure CRF1 receptor target engagement [152,153], CRF1 receptor
antagonists have failed to live up to their promise in the clinic.
There are several possible reasons for the failure of these
programs. One obvious reason could be that the disease hypothesis
has proven to be wrong, and that CRF hyper secretion is not directly
associated with MDD. Alternatively, given the biological hetero-
geneity within the MDD diagnosis, it is possible that a CRF1
receptor antagonist could have been efﬁcacious in a well-deﬁned
subpopulation of MDD patients selected by applying a CRF speciﬁc
biomarker.
Other peptide targets that originated from the stress/HPA-axis
hypothesis are neurokinin (NK)1 and NK2 receptors that are
activated by substance P and neurokinin A, respectively. NK1
receptor antagonists have had conﬂicting results in clinical trials.
Two NK1 receptor antagonists, aprepitant (MK869) and L759274,
reduced depressive symptoms in two PoC placebo-controlled
randomized double-blind phase 2 clinical trials [154,155]. Howev-
er, the efﬁcacy of aprepitant was not conﬁrmed in ﬁve subsequent
phase 2 studies [156] and the program was discontinued. Several
other NK1 receptor antagonists, including orvepitant (GW823296)
and casopitant (GW679769), were also tested for the treatment of
MDD. The phase 2 study with orvepitant was terminated in order
to assess the incidence of isolated seizure events [157]. Casopitant
showed efﬁcacy in one of the two clinical trials, but only at the
highest dose, which translated to >99% occupancy at the target
[158]. Finally, the NK2 receptor antagonist saredutant (SR48968)
was tested in ten clinical trials, either as stand-alone therapy, or in
combination with paroxetine (http://clinicaltrials.gov/show/
NCT00629551) or escitalopram (http://clinicaltrials.gov/show/
NCT00531622). Results from these clinical trials have not been
published, but the development program was discontinued in
2009 [159].
Hence, despite substantial investments in these biological
targets by several pharmaceutical companies, NK receptor
antagonists did not yield new antidepressant treatments. As
discussed with the CRF1 receptor antagonist programs, it cannot be
ruled out that a subset of MDD patients identiﬁed by means of an
appropriate biomarker might have beneﬁted from drugs with
these mechanisms. However, given the modulatory role of
neuropeptides on neurotransmission, one possibility is that
compounds that selectively target a peptide receptor are insufﬁ-
cient to treat MDD due to biological redundancies in the system.
This idea was explored using NK receptor antagonism as an
adjunctive treatment to an SSRI, but so far with limited success. A
recently published study of aprepitant with paroxetine vs. each
treatment alone did not show any advantages for the combination
in MDD patients [160].Other neuropeptide targets that have been brought forward for
evaluation in the clinic are vasopressin and orexin receptor
antagonists [161,162]. The orexin receptor antagonist ﬁlorexant
(MK-6096) was tested as an adjunctive therapy in patients
responding inadequately to an SSRI/SNRI treatment. However,
this clinical trial was terminated with no published results (https://
clinicaltrials.gov/show/NCT01554176). A clinical trial with the
vasopressin-1B receptor antagonist ABT-436 was also terminated
according to https://clinicaltrials.gov due strategic decisions not
associated with safety concerns (https://clinicaltrials.gov/show/
NCT01741142). Thus, targeting neuropeptide receptors has so far
failed to deliver new antidepressant treatments.
Several cholinergic mechanisms have been explored for the
treatment of MDD based on the cholinergic hypothesis of
depression [163] (Table 1). The hypothesis was founded on the
clinical observation that cholinomimetics can precipitate depres-
sion and on pharmacological studies in animals suggesting that the
state of depression/mania is associated with a disturbed balance
between cholinergic and adrenergic brain activity [163]. The
muscarinic cholinergic antagonist scopolamine has been recently
tested as adjunct treatment or monotherapy in clinical trials of
MDD [164–166]. It showed a rapid antidepressant response
comparable to that of ketamine. Interestingly, scopolamine’s
antidepressant activity was suggested to be mediated via increased
neuroplasticity, which would mechanistically converge with the
proposed downstream effects of ketamine [164]. As expected,
scopolamine produced typical anticholinergic adverse side effects
such as dry mouth, blurred vision and drowsiness [166], which
imply a limitation to its broad clinical use.
Another cholinergic mechanism that has been explored for the
treatment of MDD relied on the modulation of nicotinic cholinergic
receptors [167]. Both nicotinic antagonists and partial agonists
have been tested in clinical trials (Table 1), but with limited succes.
While the ﬁrst clinical study of the a4b2 nicotinic cholinergic
receptor antagonist TC-5214 (the S-enantiomer of mecamylamine)
as an add-on treatment to SSRIs was promising, subsequent clinical
studies failed to reproduce this ﬁnding and the development
program was stopped [168].
The close relation between depressed mood and hedonic
deﬁcits has led to drug proﬁles that target the reward circuitry. The
triple reuptake inhibitor programs discussed in Section 2.2 tie into
this hypothesis via their DA enhancing properties of DAT
inhibitors. Another approach that has recently obtained substan-
tial interest is kappa opioid antagonists (Table 1). Stress-induced
increase of dynorphin, the endogenous ligand for the kappa opioid
receptor, has been found to cause dysphoria in humans [169]. Fur-
thermore, preclinical studies have demonstrated that dynorphin
can reduce DA release in the nucleus accumbens and thereby cause
anhedonia-like behavior [169]. ALKS-5461, a combination of
buprenorphine (partial m opioid receptor agonist, kappa opioid
receptor antagonist) and samidorphan (m opioid antagonist), has
shown positive results in a phase 2 study [170] and is currently in
phase 3 as an augmentation therapy for the treatment of TRD
(https://clinicaltrials.gov/show/NCT02158533). The strategy be-
hind ALKS-5461 has been to reduce the m opioid receptor mediated
euphoric effect of buprenorphine by combining it with the m opioid
receptor antagonist samidorphan, and thus achieve the antide-
pressant efﬁcacy through kappa opioid antagonism. A recently
published study in MDD patients that investigated different ratios
between the two compounds indicates that a 1:1 ratio may be
optimal [171]. The positive results reported in a clinical trial of
ALKS-5461 are very encouraging and it will be important to know
whether they will repeat in the larger ongoing clinical program.
Neuroinﬂammation, another biology with linkage to MDD, has
been an area of interest for some time. The interest has been fueled
by several studies demonstrating that depressed patients have
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and TNF-a [172], and dysregulation of the kynyrenic pathway
[173]. Cyclooxygenase-2 (COX-2) inhibitors that block production
of prostaglandine E(2) and pro-inﬂammatory cytokines have been
investigated in several clinical trials of MDD. The most studied
drug celecoxib showed antidepressant efﬁcacy as an add-on
therapy to reboxetine [174], ﬂuoxetine [175] and sertraline [176]
in three small double-blind placebo controlled trials. In one study,
the adjunctive treatment with celecoxib reduced IL-6 serum levels
in depressed patients, and there was a signiﬁcant correlation
between the reduction in Hamilton Depression Rating Scale scores
and IL-6 serum levels after six weeks of treatment [176]. In
preclinical research, celecoxib was shown to potentiate the effects
of reboxetine and ﬂuoxetine on cortical NE and 5-HT levels in rats
which might provide mechanistic support for its antidepressant
efﬁcacy [177].
In addition to combined treatments with COX-2 inhibitors, the
potential of a TNF-a antibody as monotherapy has been assessed in
TRD patients in one clinical trial [178]. In that study, the TNF-a
antibody inﬂiximab did not separate from placebo, but did show a
trend toward antidepressant activity in patients with elevated
levels of inﬂammatory biomarkers at baseline [178]. Thus, this PoC
study suggests that although therapies targeting TNF-a might not
have generalized efﬁcacy in TRD, they could be used to treat
patients with high baseline inﬂammation. Taken together, these
results indicate that anti-inﬂammatory agents should be further
investigated as treatment options for MDD, especially in patients
with co-morbid inﬂammatory diseases and high levels of
inﬂammatory cytokines.
5. Target proﬁles with preclinical validation only
A substantial number of drug target proﬁles that originated
from the above discussed hypotheses of depression have been
under preclinical evaluation (Table 1). Unfortunately, there has
been a low translatability of these studies to the clinic. This could
partly be due to the fact that the majority of preclinical models rely
on behavioral changes induced by only applying physical stressors.
In spite of the long-lasting interest in monoaminergic mecha-
nisms, preclinical research is still ongoing in that ﬁeld. An
interesting, novel approach has been to reﬁne the action of
monoaminergic compounds based on the concept of selective
signaling bias. This concept originates from the observations that a
given receptor can couple to different intracellular effector
systems depending on the receptor localization, and that
compounds with selectivity for a given effector system can be
found. One such example is the 5-HT1A receptor agonist F15599
which stimulates postsynaptic 5-HT1A receptors while having no
effect on 5-HT1A somatodendritic autoreceptors [179]. As dis-
cussed in Section 2.1.1, this proﬁle would predict a rapid
antidepressant effect since it would not dampen neuronal ﬁring
in the DRN, but selectively stimulate 5-HT1A receptors in terminal
areas including the cortex and hippocampus. Another novel and
not so well explored monoaminergic mechanism is to target the
intracellularly located presynaptic traceamine-associated recep-
tor-1 (TAAR1), which is a key regulator of the release of brain
monoamines [180]. Several TAAR1 agonists have shown antide-
pressant-like activity in preclinical models of depression and
schizophrenia [180], but they have not been tested in the clinic.
As discussed in Section 3, the clinical research that emerged
from the glutamate hypothesis of depression has been primarily
focused on NMDA receptor modulation. The preclinical research
has explored additional mechanisms, including targeting of AMPA
receptors. Whereas enhanced AMPA receptor signaling plays a key
role for the induction of neuroplasticity, it is also clear that direct
stimulation of AMPA receptors can be neurotoxic [181]. Oneapproach to try to circumvent the toxicity issue has been to
develop positive allosteric modulators, also known as AMPAkines.
However, their success has been limited, in part due to low
bioavailability and toxicity issues for some of the compounds
[182,183]. Thus, it remains to be demonstrated if AMPAkines can
have a potential as antidepressants.
There is growing evidence that the endocannabinoid (endoge-
nous cannabinoid) system plays a critical role in coping with
stress-related disorders, such a depression. For instance, the
endocannabinoid system is closely linked to the glucocorticoid
system. Preclinical literature suggests that facilitation of cannabi-
noid signaling, either through stimulation of cannabinoid-1
receptors (CB1) or by inhibition of the endocannabinoid degrading
enzyme fatty acid amide hydrolase (FAAH) can produce antide-
pressant-like effects [184]. Furthermore, the CB1 receptor inverse
agonist rimonabant, which was developed and approved for
weight loss, had to be subsequently withdrawn from the market
due to risk of severe depression and suicide [185]. There have been
positive clinical observations on the antidepressant efﬁcacy of
cannabinoids, such as tetrahydrocannabinol or cannabidiol. It will
be interesting to know whether these ﬁndings can be replicated in
larger well-controlled clinical trials or by using selective CB1
receptor agonists and/or FAAH inhibitors.
Another emerging area in drug discovery research has been to
target mechanisms underlying neuronal plasticity [186]. It origi-
nates from the evidence that neuronal plasticity is important for
the recovery from depression [187]. BDNF and its receptor TrkB
(tropomyosin receptor kinase B) have been investigated exten-
sively in this regard, and positive modulators of the TrkB receptor
have been hypothesized to have antidepressant activity
[188,189]. Thus, there are several ongoing efforts to identify small
molecules with selectivity for the TrkB receptor [190]. However,
there are also preclinical reports of depressogenic-like effects of
BDNF via its negative modulation of the reward circuitry [191].
These ﬁndings question whether a TrkB receptor agonist is the
optimal proﬁle for an antidepressant, or whether an antagonist or
partial agonist would be more appropriate. Thus, more work is
needed to explore the opportunities for new antidepressant
mechanisms from this line of research.
Finally, another potentially interesting mechanism for which no
CNS drug-like molecules are available yet is chromatin remodeling
through histone deacetylase inhibition. Histone deacetylase 2
(HDAC2) inhibitors have shown antidepressant-like effects and
pro-cognitive actions in rodents [192–194]. Furthermore, an
increase in H3 acetylation and decreased levels of HDAC2 in the
nucleus accumbens have been observed in postmortem brain
tissue from depressed patients [194]. Therefore, HDAC inhibitors
should be explored further as potential targets for antidepressants,
especially once centrally penetrable tool compounds become
available [19].
6. Conclusions and future directions
Targeting the monoamine system has hitherto been the most
successful approach to treat MDD. Going beyond inhibition of MAO
and monoamine transporters has, in spite of some disappoint-
ments, produced novel and differentiated antidepressant thera-
pies, including agomelatine, vilazodone and vortioxetine, as well
add-on therapy with atypical antipsychotics. Research on gluta-
mate targets may hold promise, but is still in its early stages and
much more work is needed before we will know whether this is a
viable approach for treating MDD in the general population or
whether it will be limited to the use of ketamine in a subpopulation
of TRD patients. The preclinical observation that ketamine’s rapid
antidepressant-like activity is 5-HT-dependent [128] suggests that
a better understanding of the interface between the 5-HT and
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research strategy to pursue clinically by testing of a combination of
approved drugs that each target either the glutamate or 5-HT
systems. Several approaches (e.g., CRF, NK receptor antagonists)
have largely failed in the clinic; however these failures have
provided important knowledge about MDD. While these mecha-
nisms may be important in the etiology of depression, targeting
them in isolation is probably not sufﬁcient to treat the disorder.
Kappa opioid antagonists and neuroplasticity related targets that
are coming out of preclinical research offer promising opportu-
nities for the treatment of MDD, but additional research is needed
to validate these targets. It is possible that all of these apparently
distinct antidepressant target proﬁles ultimately converge on the
modulation of glutamate neurotransmission and its downstream
neuronal plasticity (Fig. 1). However, there are large gaps in our
understanding of the relation between glutamate physiology and
MDD, and a substantial amount of empirical data is needed to
address this hypothesis.
A rather obvious, but to some extent still neglected issue in
antidepressant research is of the importance of ensuring the
presence of therapeutic drug levels at relevant targets in the brain.
There have been multiple instances in which projects were
terminated because drugs were not tested at high enough
concentrations to reach therapeutic levels [195]. To overcome
this issue, an integrated understanding of plasma exposure, target
engagement and pharmacodynamic response is gaining momen-
tum in modern drug development. However, depending on the
target, for example the NMDA receptors, there are still methodo-
logical limitations to this approach, including difﬁculties in ﬁnding
PET ligands [196].
A shortening of the time to obtain antidepressant efﬁcacy
would be a major achievement in antidepressant research.
However, antidepressant drugs are often selected to allow for
once a day oral dosing, which implies an elimination half-life of
24 h or more. This may by default set a limit to the time to onset of
a therapeutic effect, at least if it is assumed that the therapeutic
steady-state drug level is important for the drug’s therapeutic
action at the target. Thus, ways to accelerate steady-state drug
levels and increase the initial exposure (e.g., via intravenous bolus
injection or intranasal application followed by oral maintenance)
may potentially provide faster relief of depressive symptoms and
should be clinically explored.
Even though monotherapy has been the goal for antidepressant
drug development in general, clinical practice shows the frequent
use of adjunctive therapy (pharmacological or non-pharmacologi-
cal) and several add-on therapies with atypical antipsychotics have
recently been approved for MDD. This strategy should be further
pursued during preclinical and clinical drug development, similar
to what is done in epilepsy and attention deﬁcit hyperactivity
disorder. One example could be an adjunctive treatment with N-
acetyl cysteine, which is a powerful antioxidant and an activator of
the cystine–glutamate antiporter [197]. It has shown antidepres-
sant-like properties in rodents [198] and clinical efﬁcacy in bipolar
and unipolar depression [199,200]. Another example is inhibitors
of the recently described low afﬁnity, high capacity transporters
for 5-HT in the brain, i.e. organic cation transporters (OCTs) and
plasma membrane monoamine transporters (PMATs) [201]. These
transporters are involved in the uptake of 5-HT when extracellular
5-HT levels are high and, as shown in preclinical studies, can limit
the ability of SSRIs to increase 5-HT. This ﬁeld of research is still on-
going and to our knowledge, no OCT and PMAT inhibitors have
been tested in the clinic. Needless to say, pharmacological
adjunctive treatment imposes a need to address possible drug–
drug interactions early on.
Improvement in response rates remains the major challenge in
antidepressant research. This might be accomplished through abetter understanding of the biological mechanisms underlying the
heterogeneity of MDD. Research in human genetics has so far not
succeeded in identifying biologically well-deﬁned subpopulations
in depression, but it is a rapidly advancing ﬁeld that at some point
is likely to deliver a break-through [202]. Another way forward
would be to integrate several clinical research methods to reﬁne
drug treatments, for example, by using physiological stress
response tests, measuring hormone levels (thyroid, sex hormones)
and blood biomarkers, and recording brain circuity dynamics in
depression-relevant brain regions with imaging and electrophysi-
ology techniques. However, this integrated approach may be
considered more of a long-term aspirational goal for such a
complex and heterogeneous disorder with largely unknown
etiologies as MDD.
In the area of drug discovery research, the dogma for many
years has been to ﬁrst identify a drug target and then discover and
optimize a druggable molecule. Even though more challenging
from a drug screening perspective, there are other approaches to
consider, including phenotypic screening to identify compounds
that modulate speciﬁc brain circuitries or molecules that interact
with several targets and/or receptor heterodimers. For instance, it
is known that 5-HT3 receptors form heterodimers with a4 nicotinic
receptors [203], and 5-HT2A receptors form heterodimers with
mGlu2 receptors [204]. Furthermore, even for well-known drug
targets, new opportunities may appear due to the realization that a
given receptor may couple to multiple intracellular effector
systems. Compounds can now be made with a selective signaling
bias that may allow for the targeting of speciﬁc brain areas [179].
Development and reﬁnement of non-pharmacological methods
for treatment of depression (e.g. deep brain stimulation, tran-
scranial magnetic stimulation, and cognitive behavioral therapy),
which have not been the focus of this review, have made important
advances over recent years [205,206]. Combination of pharmaco-
logical and non-pharmacological procedures is therefore a
promising therapeutic approach that could beneﬁt from larger
more systematic studies. Thus, a wealth of possibilities still exists
with regard to the development of new drug therapies for the
treatment of MDD. However, in the near term these discoveries
will likely continue to rely on empirical data and serendipity rather
than being based on a thorough understanding of the disease
etiology. Hence, basic research in understanding mechanisms of
depression should remain a high priority.
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